Cybrexa Therapeutics, a start-up cancer therapeutics company, has secured a Series B round of financing in the amount of $6 million. An investment vehicle affiliated with HighCape Partners, Connecticut Innovations, and a group of private investors participated in the round.
The Series B funding will enable Cybrexa to complete the build-out of its facilities and continue the development its tumor-localizing DNA repair inhibitors, which they refer to as Tumor Specific Drugs (TSDs).
Cybrexa was founded by Per Hellsund, Kevin Didden and Kevin Rakin, who most recently built and successfully exited Cyvek, Inc. Hellsund serves as the President and CEO, and Didden and Rakin serve as board members. Additional members of the founding team include Ranjit Bindra, M.D., Ph.D., and Peter Glazer, M.D., Ph.D., from the Yale School of Medicine.
Bindra and Glazer are both physician-scientists and world-renowned experts in DNA repair. Their work has been published in numerous high-impact journals, including Science, Nature, and Science Translational Medicine.